T-cell engagers in rheumatology - PubMed

3 hours ago

T-cell engagers (TCEs) show promise in rheumatology as a novel therapy for autoimmune diseases, extending from hematologic malignancies.
Reviewed studies involved 80 patients with conditions like SLE, RA, and SSc, with early signs of clinical improvement and biomarker normalization observed.
Challenges include persistent disease activity post-treatment, potential undertreatment due to shorter duration and lower dosing than in oncology, and cytokine release syndrome (CRS) in 46% of cases.
No neurotoxicity or deaths were reported, indicating an acceptable safety profile, but longer studies are needed to optimize dosing and assess long-term outcomes.

Hasty Briefsbeta